These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15197726)

  • 1. Re: Cabergoline versus levodopa monotherapy: a decision analysis.
    Marras C
    Mov Disord; 2004 Jun; 19(6):736. PubMed ID: 15197726
    [No Abstract]   [Full Text] [Related]  

  • 2. Cabergoline versus levodopa monotherapy.
    Wheatley K; Clarke CE; Ives N; Gray R
    Mov Disord; 2004 Jun; 19(6):733-4; author reply 734-5. PubMed ID: 15197724
    [No Abstract]   [Full Text] [Related]  

  • 3. Cabergoline versus levodopa monotherapy: a decision analysis.
    Smala AM; Spottke EA; Machat O; Siebert U; Meyer D; Köhne-Volland R; Reuther M; DuChane J; Oertel WH; Berger KB; Dodel RC
    Mov Disord; 2003 Aug; 18(8):898-905. PubMed ID: 12889079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabergoline : a review of its use in the treatment of Parkinson's disease.
    Curran MP; Perry CM
    Drugs; 2004; 64(18):2125-41. PubMed ID: 15341508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabergoline: a long-acting dopamine agonist in Parkinson's disease.
    Lera G; Vaamonde J; Muruzabal J; Obeso JA
    Ann Neurol; 1990 Oct; 28(4):593-4. PubMed ID: 2252377
    [No Abstract]   [Full Text] [Related]  

  • 6. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study.
    Utsumi H;
    Acta Med Okayama; 2012; 66(2):163-70. PubMed ID: 22525474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
    Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
    Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinical-pharmacoeconomic study of efficacy of stalevo in the treatment of Parkinson's disease with motor fluctuations].
    Levin OS; Smolentseva IG; Fedorova NV; Chigir' IP; Dokadina LV; Makhnev SO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(7):27-34. PubMed ID: 18833115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entacapone: adjunctive use in patients with advanced Parkinson's disease.
    McAuley L
    Issues Emerg Health Technol; 2000 Dec; (12):1-7. PubMed ID: 11902220
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacoeconomic aspects of using levodopa/carbidopa intestinal gel in Parkinson's disease].
    Rudakova AV; Yakupov EZ
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(10):117-21. PubMed ID: 25614914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
    Marsden CD
    Drugs; 1998; 55 Suppl 1():17-22. PubMed ID: 9483166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study.
    Romigi A; Stanzione P; Marciani MG; Izzi F; Placidi F; Cervellino A; Giacomini P; Brusa L; Grossi K; Pierantozzi M
    J Neural Transm (Vienna); 2006 Dec; 113(12):1909-13. PubMed ID: 16736238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.
    Iskedjian M; Einarson TR
    Pharmacoeconomics; 2003; 21(2):115-27. PubMed ID: 12515573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease.
    Storch A; Wolz M; Beuthien-Baumann B; Löhle M; Herting B; Schwanebeck U; Oehme L; van den Hoff J; Perick M; Grählert X; Kotzerke J; Reichmann H
    Neurology; 2013 May; 80(19):1754-61. PubMed ID: 23576623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pergolide mesylate: new therapy for Parkinson disease.
    Tanner CM; Klawans HL
    Ann Intern Med; 1982 Apr; 96(4):522-3. PubMed ID: 7065569
    [No Abstract]   [Full Text] [Related]  

  • 18. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
    Noyes K; Dick AW; Holloway RG;
    Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
    Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
    Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations.
    Hempel AG; Wagner ML; Maaty MA; Sage JI
    Ann Pharmacother; 1998 Sep; 32(9):878-83. PubMed ID: 9762373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.